DRG 593 Overview

DRG 593 covers inpatient admissions primarily for treatment of skin ulcers when a Complication or Comorbidity is present, encompassing pressure injuries, venous stasis ulcers, arterial ulcers, and diabetic foot ulcers with associated comorbid conditions. This Diagnosis-Related Group groups cases with increased resource use due to factors such as infection, poor wound healing, or significant medical comorbidity. It matters for Medicare payment because classification into this Diagnosis-Related Group affects reimbursement levels tied to expected resource consumption and length of stay. Accurate coding of the ulcer type and accompanying Complication or Comorbidity is therefore central to appropriate Medicare Severity Diagnosis-Related Group assignment.

• Acute wound care intervention trials investigating advanced dressing materials, topical biologics, or adjunctive therapies (e.g., negative pressure wound therapy) for hospitalized patients with complicated skin ulcers and a documented comorbidity that qualifies as a CC. These studies enroll inpatients with moderate-to-severe pressure injuries, venous or arterial ulcers with infection or delayed healing, often stratified by comorbidity burden (diabetes, peripheral vascular disease) to assess time to wound closure and infection control. Such research is directly relevant to providers and payers because improved acute interventions can shorten length of stay, reduce need for surgical debridement, and lower inpatient resource utilization and readmission risk.
• Comparative effectiveness studies evaluating surgical versus conservative management pathways for skin ulcers complicated by cellulitis or exposed soft tissue, including patient-centered outcomes and cost-effectiveness analyses. These trials focus on adult inpatients who meet DRG criteria due to coexisting complications, comparing outcomes such as healing rates, complication frequency, functional status, and total episode-of-care costs across different procedural approaches and perioperative protocols. Results inform clinical decision-making on optimal timing of operative debridement, antibiotic strategies, and resource allocation, helping payers and hospital leaders develop pathways that balance clinical benefit with reimbursement and utilization constraints.
• Post-discharge outcomes and care-transition studies assessing multidisciplinary outpatient follow-up models, home health interventions, and remote wound monitoring for patients discharged after an inpatient stay for skin ulcers with CCs. These prospective cohort or pragmatic trial designs enroll patients at discharge—often older adults with multimorbidity—and measure readmission rates, wound recurrence, patient adherence, and downstream costs over 30–180 days. Evidence from these studies guides providers and payers in designing discharge planning, home-care authorizations, and bundling approaches to reduce avoidable rehospitalizations and improve long-term healing and functional outcomes.